EDITAS MEDICINE, INC. Revenue
EDITAS MEDICINE, INC. (EDIT) reported Revenue of $11.89 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-05
- EDITAS MEDICINE, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $11.89M, a 232.31% increase year-over-year.
- EDITAS MEDICINE, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $2.83M, a 39.22% decline year-over-year.
- EDITAS MEDICINE, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $24.74M, a 19.16% decline year-over-year.
- EDITAS MEDICINE, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $7.54M, a 12265.57% increase year-over-year.
- EDITAS MEDICINE, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $40.52M, a 25.39% increase from fiscal 2024.
- EDITAS MEDICINE, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $32.31M, a 58.64% decline from fiscal 2023.
- EDITAS MEDICINE, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $78.12M, a 296.32% increase from fiscal 2022.
- EDITAS MEDICINE, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $19.71M, a 22.83% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.89M 10-Q · filed 2026-08-05 | $14.72M 10-Q · filed 2026-08-05 | $39.46M derived: sum of 3 quarters · filed 2026-08-05 | $47.01M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $2.83M 10-Q · filed 2026-05-05 | $27.57M derived: sum of 2 quarters · filed 2026-05-05 | $35.12M derived: sum of 3 quarters · filed 2026-05-05 | $38.69M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $24.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $32.28M derived: sum of 2 quarters · filed 2026-03-09 | $35.86M derived: sum of 3 quarters · filed 2026-08-05 | $40.52M 10-K · filed 2026-03-09 |
| 2025-09-30 | $7.54M 10-Q · filed 2025-11-10 | $11.12M derived: sum of 2 quarters · filed 2026-08-05 | $15.78M 10-Q · filed 2025-11-10 | $46.38M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $3.58M 10-Q · filed 2026-08-05 | $8.24M 10-Q · filed 2026-08-05 | $38.84M derived: sum of 3 quarters · filed 2026-08-05 | $38.90M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $4.66M 10-Q · filed 2026-05-05 | $35.26M derived: sum of 2 quarters · filed 2026-05-05 | $35.32M derived: sum of 3 quarters · filed 2026-05-05 | $35.84M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $30.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $30.66M derived: sum of 2 quarters · filed 2026-03-09 | $31.18M derived: sum of 3 quarters · filed 2026-03-09 | $32.31M 10-K · filed 2026-03-09 |
| 2024-09-30 | $61.00K 10-Q · filed 2025-11-10 | $574.00K derived: sum of 2 quarters · filed 2025-11-10 | $1.71M 10-Q · filed 2025-11-10 | $61.76M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $513.00K 10-Q · filed 2025-08-12 | $1.65M 10-Q · filed 2025-08-12 | $61.70M derived: sum of 3 quarters · filed 2025-08-12 | $67.03M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.14M 10-Q · filed 2025-05-12 | $61.18M derived: sum of 2 quarters · filed 2025-05-12 | $66.52M derived: sum of 3 quarters · filed 2025-05-12 | $69.41M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $60.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $65.39M derived: sum of 2 quarters · filed 2025-03-05 | $68.27M derived: sum of 3 quarters · filed 2025-03-05 | $78.12M 10-K · filed 2025-03-05 |
| 2023-09-30 | $5.34M 10-Q · filed 2024-11-04 | $8.22M derived: sum of 2 quarters · filed 2024-11-04 | $18.07M 10-Q · filed 2024-11-04 | $24.61M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-06-30 | $2.89M 10-Q · filed 2024-08-07 | $12.74M 10-Q · filed 2024-08-07 | $19.27M derived: sum of 3 quarters · filed 2025-03-05 | $19.32M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-03-31 | $9.85M 10-Q · filed 2024-05-08 | $16.39M derived: sum of 2 quarters · filed 2025-03-05 | $16.43M derived: sum of 3 quarters · filed 2025-03-05 | $22.79M derived: sum of 4 quarters · filed 2025-03-05 |
| 2022-12-31 | $6.54M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $6.58M derived: sum of 2 quarters · filed 2025-03-05 | $12.94M derived: sum of 3 quarters · filed 2025-03-05 | $19.71M 10-K · filed 2025-03-05 |
| 2022-09-30 | $42.00K 10-Q · filed 2023-11-03 | $6.40M derived: sum of 2 quarters · filed 2023-11-03 | $13.18M 10-Q · filed 2023-11-03 | $25.64M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $6.36M 10-Q · filed 2023-08-02 | $13.13M 10-Q · filed 2023-08-02 | $25.60M derived: sum of 3 quarters · filed 2024-02-28 | $31.80M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $6.77M 10-Q · filed 2023-05-05 | $19.24M derived: sum of 2 quarters · filed 2024-02-28 | $25.44M derived: sum of 3 quarters · filed 2024-02-28 | $25.82M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $12.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $18.67M derived: sum of 2 quarters · filed 2024-02-28 | $19.05M derived: sum of 3 quarters · filed 2024-02-28 | $25.54M 10-K · filed 2024-02-28 |
| 2021-09-30 | $6.20M 10-Q · filed 2022-11-02 | $6.58M derived: sum of 2 quarters · filed 2022-11-02 | $13.07M 10-Q · filed 2022-11-02 | $24.49M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $379.00K 10-Q · filed 2022-08-03 | $6.88M 10-Q · filed 2022-08-03 | $18.30M derived: sum of 3 quarters · filed 2022-08-03 | $81.14M derived: sum of 4 quarters · filed 2022-08-03 |
| 2021-03-31 | $6.50M 10-Q · filed 2022-05-04 | $17.92M derived: sum of 2 quarters · filed 2022-05-04 | $80.76M derived: sum of 3 quarters · filed 2022-05-04 | $91.51M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $11.42M 10-K · filed 2021-02-26 | $74.26M derived: sum of 2 quarters · filed 2021-11-09 | $85.01M derived: sum of 3 quarters · filed 2021-11-09 | $90.73M 10-K · filed 2023-02-22 |
| 2020-09-30 | $62.84M 10-Q · filed 2021-11-09 | $73.59M derived: sum of 2 quarters · filed 2021-11-09 | $79.31M 10-Q · filed 2021-11-09 | $91.60M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $10.75M 10-Q · filed 2021-08-05 | $16.47M 10-Q · filed 2021-08-05 | $28.76M derived: sum of 3 quarters · filed 2021-08-05 | $32.60M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $5.72M 10-Q · filed 2021-05-06 | $18.01M derived: sum of 2 quarters · filed 2021-05-06 | $21.86M derived: sum of 3 quarters · filed 2021-05-06 | $24.18M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $12.28M 10-K · filed 2021-02-26 | $16.13M derived: sum of 2 quarters · filed 2021-02-26 | $18.46M derived: sum of 3 quarters · filed 2021-02-26 | $20.53M 10-K · filed 2022-02-24 |
| 2019-09-30 | $3.85M 10-K · filed 2021-02-26 | $6.18M derived: sum of 2 quarters · filed 2021-02-26 | $8.25M 10-Q · filed 2020-11-06 | $14.37M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $2.33M 10-K · filed 2021-02-26 | $4.40M 10-Q · filed 2020-08-07 | $10.52M derived: sum of 3 quarters · filed 2021-02-26 | $25.04M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $2.07M 10-K · filed 2021-02-26 | $8.19M derived: sum of 2 quarters · filed 2021-02-26 | $22.71M derived: sum of 3 quarters · filed 2021-02-26 | $30.08M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $6.12M 10-K · filed 2020-02-26 | $20.64M derived: sum of 2 quarters · filed 2020-02-26 | $28.01M derived: sum of 3 quarters · filed 2020-02-26 | $31.94M 10-K · filed 2021-02-26 |
| 2018-09-30 | $14.52M 10-K · filed 2020-02-26 | $21.89M derived: sum of 2 quarters · filed 2020-02-26 | $25.82M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $7.37M 10-K · filed 2020-02-26 | $11.30M 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | $3.93M 10-K · filed 2020-02-26 | |||
| 2017-12-31 | $13.73M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |